498. Baricitinib in Patients with Severe Pneumonia due to COVID-19 in Veracruz, Mexico

BACKGROUND: Patients affected by COVID-19 pneumonia who present severe symptoms with manifest hypoxemia and cytokine storm have a high mortality rate, which is why therapies focused on reducing inflammation and improving lung function have been used, one of them being jakinibs through of the blockin...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Carpio-Orantes, Luis, García-Méndez, Sergio, Zamudio-Severino, Gustavo Miguel, Sánchez-Díaz, Jesús Salvador, Navarrete-Espinosa, Benito, Rivera-Viñas, Miguel Ángel, Salas-González, Arturo, aguilar-silva, Andrés, Cruz-Albarrán, Sonia, Denis-Bravo, Jorge Luis, Esparza-Mora, Iván, González-Medel, Karem Samantha, Hernández-Zaleta, Nelyda Verania, López-Cruz, Edgar Alberto, Montano-Montiel, Laura Guadalupe, Morgado-Hernández, Jennifer Ivonne, Muñoz-Aguilar, José Alberto, Priego-Parra, Edson Irving, Reich-Sierra, Reynaldo, Sánchez-Jiménez, Noel Jhosimar, Tress-Uc, María Fernanda, Velázquez-Orozco, Paola, Contreras-Sánchez, Edna Rosario, Medrano-Rios, Luis Jaime, Ruiz-Castro, Enrique, Ortiz-Hernández, Manuel Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690645/
http://dx.doi.org/10.1093/ofid/ofab466.697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690645/
http://dx.doi.org/10.1093/ofid/ofab466.697

Ejemplares similares